Novartis AG (NYSE:NVS) – Investment analysts at Jefferies Group issued their Q3 2017 earnings per share (EPS) estimates for shares of Novartis AG in a report issued on Wednesday. Jefferies Group analyst J. Holford expects that the company will earn $1.24 per share for the quarter. Jefferies Group also issued estimates for Novartis AG’s FY2020 earnings at $6.58 EPS and FY2021 earnings at $7.50 EPS.

Novartis AG (NYSE:NVS) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.06. The company had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The firm’s quarterly revenue was down 1.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.23 earnings per share.

COPYRIGHT VIOLATION WARNING: “Novartis AG (NVS) to Post Q3 2017 Earnings of $1.24 Per Share, Jefferies Group Forecasts” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/05/novartis-ag-nvs-to-post-q3-2017-earnings-of-1-24-per-share-jefferies-group-forecasts.html.

A number of other equities analysts have also recently commented on the company. Zacks Investment Research cut Novartis AG from a “hold” rating to a “sell” rating in a report on Monday, July 10th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research note on Tuesday, August 29th. Credit Suisse Group lowered Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 price target for the company. in a research note on Wednesday, July 5th. Morgan Stanley upgraded Novartis AG from an “underweight” rating to an “overweight” rating in a research note on Wednesday, July 26th. Finally, Leerink Swann reiterated a “market perform” rating and issued a $83.00 price target on shares of Novartis AG in a research note on Thursday, June 22nd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $85.12.

Novartis AG (NVS) opened at 86.07 on Thursday. The stock has a 50 day moving average price of $84.73 and a 200 day moving average price of $81.29. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The stock has a market capitalization of $201.65 billion, a PE ratio of 31.42 and a beta of 0.73.

Institutional investors have recently modified their holdings of the company. Westwood Holdings Group Inc. grew its position in shares of Novartis AG by 5.6% during the first quarter. Westwood Holdings Group Inc. now owns 5,405 shares of the company’s stock valued at $401,000 after purchasing an additional 285 shares in the last quarter. GFS Advisors LLC grew its position in shares of Novartis AG by 6.5% during the second quarter. GFS Advisors LLC now owns 21,314 shares of the company’s stock valued at $1,779,000 after purchasing an additional 1,300 shares in the last quarter. Mechanics Bank Trust Department purchased a new position in shares of Novartis AG during the second quarter valued at about $389,000. ProVise Management Group LLC grew its position in shares of Novartis AG by 12.2% during the second quarter. ProVise Management Group LLC now owns 85,041 shares of the company’s stock valued at $7,099,000 after purchasing an additional 9,227 shares in the last quarter. Finally, Union Bankshares Corp grew its position in shares of Novartis AG by 0.3% during the second quarter. Union Bankshares Corp now owns 37,521 shares of the company’s stock valued at $3,132,000 after purchasing an additional 99 shares in the last quarter. Hedge funds and other institutional investors own 10.93% of the company’s stock.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Earnings History and Estimates for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.